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Abstract
Background: Microcystic macular edema (MME) and inner nuclear layer thickening (INL) were described in multiple sclerosis
(MS) and neuromyelitis optica (NMO) patients using optical coherence tomography (OCT). The cause of these findings is
currently unknown and a relation to inflammatory or degenerative processes in the optic nerve is discussed.
Objective: The aim of our study was to investigate whether INL thickening and MME are related to optic neuritis (ON) in
various neuro-inflammatory disorders causingON: MS, NMO and chronic inflammatory optic neuropathy.
Methods: We retrospectively analyzed data from 216 MS patients, 39 patients with a clinically isolated syndrome, 20 NMO
spectrum disorder patients, 9 patients with chronic inflammatory optic neuropathy and 121 healthy subjects. Intra-retinal
layer segmentation was performed for the eyes of patients with unilateral ON. Scanning laser ophthalmoscopy (SLO) images
were reviewed for characteristic ocular fundus changes.
Results: Intra-retinal layer segmentation showed that eyes with a history of ON displayed MME independent INL thickening
compared to contralateral eyes without previous ON. MME was detected in 22 eyes from 15 patients (5.3% of all screened
patients), including 7 patients with bilateral edema. Of these, 21 had a prior history of ON (95%). The SLO images of all 22
MME-affected eyes showed crescent-shaped texture changes which were visible in the perifoveal region. A second grader
who was blinded to the results of the OCT classified all SLO images for the presence of these characteristic fundus changes.
All MME eyes were correctly classified (sensitivity = 100%) with high specificity (95.2%).
Conclusion: This study shows that both MME and INL thickening occur in various neuro-inflammatory disorders associated
with ON. We also demonstrate that detection and analysis of MME by OCT is not limited to B-scans, but also possible using
SLO images.
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Introduction
Optic neuritis (ON) is a common symptom of inflammatory
central nervous system disorders that often heralds a diagnosis of
multiple sclerosis (MS) or neuromyelitis optica (NMO) [1–5]. In
both diseases, ON can cause irreversible damage to axons in the
retina and their neurons, the retinal ganglion cells, which can be
quantified by optical coherence tomography (OCT) [6–10]. A
number of OCT studies have demonstrated retinal neuro-axonal
damage in MS patients with and without a history of ON, as well
as in NMO patients [7,8,11–18]. Thanks to recent technical
advances in OCT, including improved resolution and intra-retinal
layer segmentation, pathologies can be detected in various retinal
layers, such as the retinal ganglion cell layer (GCL) and the inner
nuclear layer (INL) [19–24]. The new data this has yielded have
substantially advanced our understanding of retinal pathology in
MS, leading to intriguing, new hypotheses regarding MS
pathophysiology [19].
Recently, a retinal finding termed microcystic macular edema
(MME) was observed in MS [25,26]. While this paper was under
review, two further studies reported MME in NMO [27,28]. In all
studies, MME was predominantly located in the INL and was
associated with reduced visual acuity and retinal nerve fiber layer
(RNFL) thinning in both disorders. In MS, the INL was shown as
a prominent site of retinal and microglial inflammation [29],
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which led the authors to propose MME as a clinical correlate of
pathological processes in the INL. Indeed, an earlier study had
already reported an correlation between INL thickening at
baseline with more severe disease progression, as measured by
increased development of contrast-enhancing lesions, new T2
lesions, Extended Disability Status Scale (EDSS) [30] progression
and relapses in patients with relapsing-remitting MS over the study
period [26]. However, other reports have countered these findings,
arguing that MME may not be MS- or NMO-specific [31] or even
that it is entirely independent of inflammation and instead based
on acute optic neuropathy e.g. mediated by mechanical stress
[32,33].
Against this background, our first aim was determining whether
INL thickening only occurs in MME and whether it is related to a
previous episode of ON, which would suggest that ON is as a
causative factor in INL pathology. We screened patients with three
different neuro-inflammatory disorders including ON: MS, NMO
and chronic relapsing inflammatory optic neuropathy (CRION)
[34]. Secondly, we report that MME can be detected and
quantified more easily in fundoscopic scanning laser ophthalmos-
copy (SLO) images than on OCT B-scans, which has the potential
to make screening and analysis of MME in research and clinical
routine more robust.
Methods
Patients
Scans acquired between June 2010 and August 2012 archived in
the NeuroCure Clinical Research Center’s OCT database were
screened for MME. The study included 216 MS patients
diagnosed according to the revised 2005 McDonald criteria
[35], 20 NMO-spectrum disorder (NMOSD) patients diagnosed
according to current diagnostic criteria [36,37], 39 patients with
clinically isolated syndrome (CIS), as identified by application of
the revised McDonald criteria [38], 9 patients diagnosed with
CRION and 121 healthy subjects. All NMOSD patients were
tested for the presence of antibodies against aquaporin-4 (AQP4)
in at least one of several assays, of which 16 tested positive (80%).
Some ophthalmologic features of 17 patients from the NMOSD
cohort have been previously reported by Schneider et al. [39].
Inclusion criteria were a history of ON or lack of ON clearly
confirmed by medical records. In contrast, exclusion criteria were
other neurological, ophthalmological and systemic diseases that
damage the optic nerve or retina (i.e. glaucoma, diabetes, age-
related macular degeneration, epiretinal membranes) or a history
of fingolimod treatment, which is suspected to cause macular
edema [40,41]. Clinical data, including disease duration and
current medical treatment, were compiled as part of a compre-
hensive neurological examination under the supervision of a
board-certified neurologist. MS patients were classified for MS
subtypes according to the Lublin criteria [42]. Neurological
disability was assessed using EDSS [30] and the Global Multiple
Sclerosis Severity Score (MSSS) [43]. Finally, the high-contrast
visual acuity of all subjects was quantified using Snellen charts or
ETDRS charts [44].
Ethics Statement
The study was approved by the local ethics committee of the
Charite´ – Universita¨tsmedizin Berlin and was conducted in
accordance with the Declaration of Helsinki in its current version,
the guidelines of the International Conference on Harmonisation
of Good Clinical Practice (ICH-GCP) and applicable German
laws. All participants gave informed, written consent.
Optical Coherence Tomography
Peripapillary RNFL thickness (pRNFL) and macular volume
scans were performed using a spectral-domain OCT (Heidelberg
Spectralis, Heidelberg Engineering, Germany, Heidelberg Eye
Explorer viewing module versions 5.2.4.0–5.6.1.0) of each patient
or healthy subject’s eyes. pRNFL thickness was measured with a
12u circular scan (approx. 3.4 mm diameter) around the optic
nerve head obtained using the device’s standard protocol and
segmentation algorithm with activated eye tracker. Whenever
possible, the maximum number of averaging frames in the
automatic-real-time mode (ART) was used. Macular volume was
measured using a custom protocol that generated 61 vertical slices
(B-scans) focusing the fovea, at scanning angle of 30u625u and a
resolution of 768 A-scans per B-scan. As this scan protocol limits
averaging frames to 13, the sensitivity should be sufficient to detect
MME in B-scans, which might be undetectable at higher ART
settings [25]. Total macular volume (TMV) was calculated by
estimating the distance between the inner limiting membrane and
Bruch’s membrane in a 6 mm-diameter cylinder using the OCT
software’s segmentation algorithm. All scans were acquired by
experienced operators and were evaluated for sufficient signal
strength, correct centering and segmentation based on the
OSCAR-IB criteria by a second operator [45]. In total, 12 eyes
of 12 different subjects (5 MS; 1 NMOSD; 6 healthy controls) had
no usable OCT scan (neither RNFL circle nor macular volume
scan) and were completely excluded from analysis for one of the
following reasons: the RNFL scans of two eyes were truncated, one
fundus image was weakly illuminated and another RNFL scan was
not correctly centered and no eye-tracker had been used. The
remaining RNFL and all macular volume scans had not been
performed or archived because of lack of patient compliance or, in
case of healthy controls, due to time constraints.
To identify eyes with MME, one operator applied the criteria
published by Gelfand and colleagues [25] and reviewed all
macular scans according to these criteria. MME was defined as
clearly limited, insular and cystoid areas of hyporeflectivity in two
or more consecutive B-scans. Shadowing in the retinal layers
below the cystoid abnormalities was a second but optional
criterion for MME inclusion. Blood vessels shadows were excluded
as MME criterion.
Furthermore, we investigated the influence of MME and
previous ON on the thickness of the inner retinal layers. Retinal
layer segmentation was performed for patients with MME (n= 15)
or with a previous unilateral ON event (excluding the patients with
MME) (n= 75) and for 39 healthy controls. Controls were age-
(63 years) and gender-matched to patients with unilateral ON
without MME and were chosen from all controls using the
optmatch R package. Here, for each eye, the central B-scan
through the fovea and every fourth B-scan in temporal and nasal
direction were automatically segmented (Heidelberg Software
1.7.1.0), reviewed and manually revised by two graders to correct
any overt segmentation errors. Both graders were blinded as to
subject identity and clinical status (ON or eyes without a history of
ON (NON)). In addition, graders were not aware which eyes were
belonging together but in all cases, one and the same grader
corrected both eyes of an individual subject The average layer
thicknesses of the macular RNFL (mRNFL), the combined
ganglion cell and inner plexiform layer (GCIPL) and the INL
were assessed for the area calculated in the earlier TMV
estimation. Grader consistency was estimated using 10 randomly
selected patient eyes (all MS) each corrected by both graders.
Intraclass correlation coefficients were 0.997 for the mRNFL and
0.999 for both the GCIPL and INL.
ON Association with MME and INL
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MME Detection in OCT SLO Images
While screening OCT B-scans for MME the operator (FK)
detected distinct changes of the ocular fundus in the SLO-images
from eyes diagnosed with MME using the Spectralis built-in
confocal SLO (wavelength = 820 nm). In a second step, an
independent reviewer (HZ) familiar with the SLO findings from
a sample SLO image but blinded to the MME results from OCT
scans screened all SLO images from the database. MME was
considered present, if the SLO images showed: (i) a darker and
dot-like pattern in the macular area compared to the surrounding
tissue, and (ii) crescent-like configurations spanning parts of the
macula around the fovea (see Results and Figure 1). A third
operator (TO) quantified the affected SLO areas using ImageJ
(version 1.44). A rigorous blinding procedure was followed to
Figure 1. Sample scans showing MME in SLO and OCT images. Sample SLO images (on the left) and sample OCT B-scan images (on the right)
from A) MS patient’s eye with a history of ON but without MME, B) an MS patient’s eye with history of ON and MME, C) an NMO patient’s eye with
history of ON and MME and D) an eye from a patient with CRION and MME. Whereas the eye from A does not show any signs of MME in either the
SLO or OCT B-scan image, all eyes in B-D show similar findings. The SLO images were mirrored where necessary to standardize orientation.
doi:10.1371/journal.pone.0071145.g001
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ensure classification by the three operators remained independent.
All operators were blinded for age, gender, disease and ON
history. All SLO-image evaluators were blinded to the corre-
sponding OCT images and to the result of MME OCT screening.
Statistical Analysis
Comparison of age and EDSS between cohorts was performed
using the Mann-Whitney-U test. Gender differences were assessed
with Pearson’s chi-squared test. Association between SLO area
size and visual acuity, time since last ON, pRNFL thickness and
TMV were analyzed using generalized estimating equation models
(GEE) to account for inter-eye/intra-patient dependencies using
Table 1. Demographic overview of the study cohort.
Parameter MME patients Non-MME patients HC
Subjects Total (N) 15 268 121
MS (N) 7 209 –
CIS (N) 0 38 –
NMO (N) 3 17 –
CRION (N) 5 4 –
Age (years) Mean 6 SD 40610 42611 36612
Min – Max 23–54 17–72 20–68
Gender (female/male) N/N 12/3 171/97 83/38
Disease Duration (months) Mean 6 SD 1256111 83679 –
Min – Max 10–317 0–403 –
MS-Subtypes RRMS (N) 3 163 –
SPMS (N) 4 31 –
PPMS (N) 0 15 –
Abbreviations: MME=microcystic macular edema; MS =multiple sclerosis; NMO=neuromyelitis optica spectrum diseases; CRION= chronic relapsing inflammatory
optic neuropathy; HC =healthy control; RRMS= relapsing-remitting multiple sclerosis; SPMS = secondary-progressive multiple sclerosis; PPMS =primary-progressive
multiple sclerosis; CIS = Clinical isolated syndrome; SD= standard deviation; Min =minimum value; Max =maximum value.
doi:10.1371/journal.pone.0071145.t001
Table 2. Ocular key data of MME and non-MME eyes.
Parameter MME eyes Non-MME eyes a) HC eyes
Number of eyes Total (N) 22 538 236
MS (N) 11 416 –
CIS (N) 0 76 –
NMO (N) 4 35 –
CRION (N) 7 11 –
ON prevalence Total N (%) 21 (95.5) 186 (34.6) –
MS N (%) 10 (90.9) 150 (36.1) –
CIS N (%) – 15 (19.7) –
NMO N (%) 4 (100) 15 (42.9) –
CRION N (%) 7 (100) 6 (54.5) –
Time since last ON (months) Mean 6 SD 1006100 – –
Min – Max 1–304 – –
Visual acuity Mean 6 SD 0.3160.38 1.0560.37 1.1760.39
Min – Max 0–1.25 0.01–1.6 0.13–1.6
pRNFL thickness (mm) Mean 6 SD 51.6612.5 87.5615.65 98.468.49
Min – Max 31.8–78.2 29.1–129.9 79.9–120.0
TMV (mm3) Mean 6 SD 8.0060.41 8.4060.44 8.6760.33
Min – Max 7.23–8.78 7.06–9.37 7.72–9.47
a)The contralateral eyes of unilateral MME eyes were excluded.
Abbreviations: MME=microcystic macular edema; MS =multiple sclerosis; NMO=neuromyelitis optica spectrum diseases; CRION= chronic relapsing inflammatory
optic neuropathy; ON= optic neuritis; pRNFL = peripapillary retinal nerve fiber layer; TMV= total macular volume; SD= standard deviation; Min =minimum value;
Max =maximum value.
doi:10.1371/journal.pone.0071145.t002
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the working correlation matrix ‘‘exchangeable’’. In all GEE
models, the SLO area was set as dependent variable. Likewise,
group differences in visual acuity and OCT results were calculated
using GEE models. Provided parameters from GEE models are
effect size (B), standard error (SE) and significance (P). Frequency
of MME occurrence was compared between the cohorts using
Fisher’s exact tests. Comparison of intra-patient/inter-eye differ-
ences was performed using the two-sided paired Wilcoxon signed
rank test. Correlation of mRNFL and GCIPL differences to the
INL differences was analyzed using linear regression models.
Statistical tests were performed with IBM SPSS 20 (IBM, Armonk,
NY, USA) or R (basic package ver. 2.15.2, including the packages:
geepack (ver. 1.1.6), ggplot2 (ver. 0.9.3) and optmatch (ver. 0.8.1)).
Statistical significance was established at P,0.05. As ours was an
exploratory study, no power calculation had previously been
performed, and the disorders of all included groups are related and
their features therefore likely correlate, no correction for multiple
comparisons was performed.
Results
Based on the criteria defined by Gelfand and colleagues [25],
we identified MME in 22 eyes from 15 patients. Of these patients,
5 had been diagnosed with CRION, 3 with NMOSD and 7 with
MS. No MME was observed in healthy controls and the screened
CIS patients. A demographic overview of the study cohort is
presented in Table 1. MME appeared bilaterally in 7 of the 15
patients and was located exclusively in the inner nuclear layer of
the retina, between 925 mm and 2,200 mm (mean 6 SD:
1,6026351 mm) distal to the foveal center. The maximum cyst
diameter was 81 mm (mean 6 SD: 45614 mm).
MME is Associated with ON
A prior history of ON was found in all MME-affected patient
eyes, with one exception (95.5%). In the latter case, the patient had
been diagnosed with secondary progressive MS and reported
experiencing visual disturbances in the eye during the 1980s. The
most recent documented VEP from this eye had a latency of
116 ms. Eyes with MME showed reduced visual acuity (P=0.010),
along with decreased pRNFL thickness (P,0.001) and TMV
(P,0.001), compared to eyes unaffected by MME. A summary of
the key ocular data of the MME and non-MME eyes, including
ON prevalence, visual acuity, pRNFL thickness and TMV
measures, is given in Table 2.
Frequency of MME in ON Eyes
In MS patients, 6.3% of all eyes with a history of ON showed
MME, compared to 21.0% of all NMOSD patients’ eyes with a
history of ON. MME prevalence was highest in CRION patients
at 53.8% of all eyes of patients with a history of ON. The
prevalence of MME was significantly different between MS and
CRION patients (P,0.001), but not between MS and NMOSD
patients (P=0.068), or between NMOSD and CRION patients
(P=0.295).
ON Eyes with MME are More Severely Affected
In eyes with a history of ON, MME-affected eyes showed
significantly reduced pRNFL thickness (mean 6 SD:
77.5615.8 mm, P,0.001) and visual acuity (mean 6 SD:
1.060.39, P=0.049) and non-significantly reduced TMV (mean
6 SD: 8.1560.43 mm3, P=0.155), compared to eyes unaffected
by MME.
Eyes with pRNFL below the first quartile of all ON eyes
(Q1= 64.6 mm) were categorized as having a severe history of ON,
which was a strong predictor for the development of MME (odds
ratio = 13.6, 95% CI= 4.7–39.7).
Disease Severity in MS-ON Patients with and without
MME
MS patients with MME were later in the disease course with a
higher rate of secondary progressive patients (P=0.01) and had
significantly higher EDSS and MSSS scores (Table 3), compared
to MS patients with a history of ON but no MME.
Comparison of Retinal Layer Thickness between Patient
Eyes with MME, Unilateral History of Optic Neuritis and
Healthy Controls
Based on medical records, 75 patients (11 CIS, 44 RRMS, 9
SPMS, 4 CRION, 7 NMOSD) had previously experienced an
unilateral ON event (excluding patients with present MME). The
mean age of this group was 38.9 years (SD=10.5 years), which
was not significantly different from the matching controls
(mean=38.1 years; SD=11.1 years; P=0.639). The gender
composition in patients (47 female, 28 male) and controls (24
female, 15 male) did also not differ between both cohorts
(P=0.999). The results of the intra-retinal layer segmentation of
patients with unilateral ON, patients with MME and the matching
controls are shown in Table 4. Unsurprisingly, the ON-affected
eyes showed reduced mRNFL and GCIPL thickness compared to
the unaffected contralateral eyes (both P,0.001). INL thickness
Table 3. Disease severity in MS patients.
MME MS patients Non-MME MS-ON patients P-value
Subjects N 7 100
MS subtype RRMS (N)/SPMS (N) 3/4 87/13 0.012
EDSS Median 5 2.25 0.002
Min - Max 2.5–6.5 0–6.5
Disease duration (months) Mean 6 SD 172.146109.44, 114.38683.59, 0.174
Min - Max 45–303 2–403
MSSS (mean +- SD, min - max) Mean 6 SD 5.9961.88 3.8162.06 0.011
Min - Max 3.69 8.83 0.22–8.3
Abbreviations: MME=microcystic macular edema; MS =multiple sclerosis ON=optic neuritis; SD = standard deviation; Min =minimum value; Max =maximum value;
EDSS = Expanded Disability Status Scale; MSSS =Multiple Sclerosis Severity Score.
doi:10.1371/journal.pone.0071145.t003
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was increased in ON eyes without MME compared to contralat-
eral NON eyes (P,0.001). We did not perform statistical testing of
all disease cohorts separately, due to the relatively small sample
size in some groups, but Figure 2A represents that – with some
exceptions – ON eyes showed INL thickening in patients across all
disease sub-groups. The intra-patient/inter-eye differences in INL
were inversely correlated to mRNFL (R2= 0.0863; P,0.001,
linear regression, Figure 2B) and GCIPL inter-eye differences
(R2 = 0.0431; P=0.011, Figure 2C).
Eyes with MME showed a more severe reduction in mRNFL
and GCIPL thickness compared to controls and also to non-MME
eyes with a previous unilateral ON, while the INL thickness was
increased in patients with MME-affected eyes compared to
controls and eyes with a history of unilateral ON (all P,0.001,
Table 4).
Characteristics of MME in OCT SLO Images
The SLO images showed dark, dotted patterns in the ocular
fundus in all 22 MME-affected eyes. These generally presented in
a crescent shape around the fovea, which was itself recessed.
Sample SLO images and their corresponding B-scans are shown in
Figure 1.
To test the sensitivity and specificity of using these SLO changes
to diagnose MME compared to using OCT B-scans, a second
experienced operator screened all SLO images in a blinded
fashion and was able to correctly classify all MME-affected eyes
originally identified by OCT B-scans with no false negatives
(sensitivity = 100%). An additional 27 eyes (from 17 subjects) not
identified as potential MME eyes using OCT B-scans were flagged
in the SLO analysis (specificity = 95.2%). Three of these eyes
showed suspicious MME structures, but did not fulfill the criterion
of visible microcysts on two adjacent B-scans.
MME Size Correlates with Visual Acuity
Alterations found in SLO images featured mostly clear contours
that allowed us to quantify their area, which ranged from 1.7 to
11.1 mm2 (mean 6 SD: 5.962.3 mm2; Figure 3A). Figure 3B
maps the corresponding points of microcysts in OCT B-scans and
SLO images. In GEE models, time since last ON in months
(B =20.1, SE=0.04, P=0.025) was a significant, inverse predic-
tor for the size of MME-affected area shown in the SLO image. In
other words, the shorter the time between the ON event and the
OCT scan the larger the MME-affected area shown in the SLO
image. Secondly, the size of the MME-affected area shown by
SLO was in turn inversely correlated with visual acuity (B=22.2,
SE= 0.9, P=0.012). In contrast, there was no correlation between
SLO area and pRNFL thickness (P=0.943) or TMV (P=0.233).
Discussion
In this study we investigated the occurrence of INL changes
including MME in neuro-inflammatory diseases associated with
optic neuritis. Our main findings are: a) MME was almost
exclusively limited to patients with a history of ON, regardless of
the underlying nosologic entity, and – with the exception of one
case – only occurred in eyes previously affected by ON; b) eyes
without MME but with previous ON displayed INL thickening in
Figure 2. Inter-eye differences in patients with unilateral
history of optic neuritis. A) Differences in inner nuclear layer (INL)
thickness between affected and unaffected eyes of patients with a
unilateral history of optic neuritis categorized by diagnosis. Eyes
belonging to one patient are connected by lines. Lines in blue indicate
eyes, which the INL of the optic neuritis eyes was thicker compared to
the contralateral unaffected eyes, whereas red lines show the contrary.
B) Correlation of inter-eye INL thickness differences with inter-eye
macular retinal nerve fiber layer (mRNFL) thickness differences (LR:
P,0.001). C) Correlation of inter-eye INL thickness differences with
inter-eye ganglion cell and inner plexiform layer (GCIPL) thickness
differences (LR: P = 0.011).
doi:10.1371/journal.pone.0071145.g002
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comparison to contralateral eyes without a history of ON; c) MME
was easily detected and quantified using fundoscopic SLO images;
d) the size of the affected MME-area in SLO images correlated
inversely with the length of time since the last ON event and with
visual acuity.
Previous studies investigating MME in MS patients have found
higher ON frequencies in MME eyes compared to unaffected eyes
[25,26]. For example, in one study, 50% of MME-affected eyes of
MS patients had a history of ON, while two studies found past
history of ON in 100% of the MME-affected NMO eyes [27,28].
In line with these findings, our data showed that almost all MME
eyes had a history of ON, not only in NMO but also in MS and
CRION patients. Overall, MME was more common in NMO and
CRION than MS patients. This strongly points to a pathophys-
iological correlation between the development of MME and the
extent of damage to the optic nerve, which would suggest that
MME may result from ocular inflammation during or following
ON, irrespective of the underlying nosologic entity. The finding
that eyes with more severe optic neuritis were more likely to
exhibit MME could indicate that the latter is an extreme
manifestation of INL pathology, found in milder form as INL
thickening in the majority of ON eyes. The fact that all previous
studies have reported significantly reduced RNFL for MME-
affected eyes, which is a common feature of ON-affected eyes,
lends weight to our hypothesis [14]. Notably in this context, the
only MME-affected eye in our study without a reported previous
clinical ON event was that of an MS patient with long disease
duration and a secondary progressive course. However, in this
case, a previously recorded prolonged VEP latency and reports of
visual disturbances in the past also suggest a subclinical ON event.
Importantly, previous studies did not detect general INL
thickening in ON eyes from MS or NMO patients in comparison
to healthy controls or non-ON eyes [26,27], probably due to the
higher inter-individual variation compared to the effect size. One
study found INL thinning in primary progressive MS patients
compared to healthy controls, but not in other MS types [46].
Pairwise comparison of eyes from patients with only unilateral ON
and no present MME consistently showed INL thickening in the
eye with previous ON compared to its ON-unaffected counterpart,
and was also true for MS, CRION and NMOSD patients alike. In
MS, INL thickening has been previously reported to be correlated
with higher inflammatory activity and more severe disease
progression [26]. Whether the former was mainly a result on the
more aggressive inflammatory activity in these patients, as
suggested by Saidha et al. (i.e. MS patients with higher
inflammatory activity could also have more clinical or subclinical
ON episodes or other ocular inflammation, such as uveitis or
periphlebitis that could be mistaken for optic neuritis) or represents
an additional pathology requires further investigation. In our
study, thinner INL in eyes with a history of ON compared to the
contralateral eyes was only found in a few cases. Although a clear
explanation for these exceptions is not evident from our data, but
one reason might be that subclinical ON events not documented
or reported by the patient had skewed our analysis.
Histopathological data on retinal pathology in MS have been
provided in a comprehensive work by Green et al. [29]. Here, the
INL was identified as a prominent site of reduced neuronal cell
count, inflammation and microglial activation, presumably giving
rise to development of microcystic edema. However, histopatho-
logical findings of reduced neuronal cell count may not necessarily
translate into reduced thickness in vivo, since histopathology allows
only quantification of cell counts, but not of tissue layer
thicknesses. The latter parameter is usually lost or altered during
the fixation process. It can be assumed that specific layer
properties of the INL, including the presence of bipolar cells,
promote loosening of intra-layer adhesion and in some cases even
cause microcystic alterations or edematous changes, such as
described by Gelfand and colleagues [25]. Whether the observed
INL alterations are induced by bipolar cells, Mu¨ller cells,
horizontal cells, amacrine cells and/or changes of the extracellular
matrix, remains to be clarified. Of the latter, Mu¨ller cells indeed
play a crucial role, as their dendrites are in contact with all other
retinal layers and mediate the protective or detrimental processes
of other retinal cells [47]. Overall, further studies are required to
bridge the gap between post-mortem analyses of human retinal
tissue and in vivo OCT.
The potential inflammatory etiology of INL changes posited by
the paper of Gelfand et. al. [25] was challenged in two reply letters
which reported retinal microcystic changes in non-inflammatory
diseases affecting the optic nerve, leading the authors to propose
alternative underlying pathomechanisms. Abegg et al. discussed
MME as a possible consequence of optic nerve degeneration in
optic nerve glioma [33], whereas Barboni et al. proposed vitreous
traction, resulting in a schesis stretching the INL in Leber9s
hereditary optic neuropathy [32]. Both claimed that the resulting
findings were identical to those reported for MS and NMO and
would thus argue against disease specificity. Indeed, the included
imaging data exhibited striking similarities to MME in MS, NMO
and CRION. However, the small sample size and anecdotal
nature of the two case reports presented in the letters hampers
assessment of the proposed hypotheses [48]. Larger studies are
needed to determine whether the described findings are indeed
Table 4. Results of the retinal segmentation for patients with a history of unilateral ON, patients’ eyes with MME and controls.
HC eyes MME eyes Non-ON eyes ON eyes
ON vs. NON eyes P
value (paired
Wilcoxon)
MME vs. HC
eyes P value
(GEE)
MME vs. ON
eyes
P value (GEE)
Number of eyes 78 22 75 75
Mean mRNFL thickness (SD)
[in mm]
38.4 (3.8) 22.6 (2.5) 35.4 (5.1) 29.4 (5.8) ,0.001 ,0.001 ,0.001
Mean GCIPL thickness (SD)
[in mm]
70.4 (5.5) 48.1 (5.7) 66.0 (6.9) 57.1 (9.0) ,0.001 ,0.001 ,0.001
Mean INL thickness (SD)
[in mm]
33.0 (2.5) 39.0 (3.2) 33.9 (2.4) 34.5 (2.6) ,0.001 ,0.001 ,0.001
Abbreviations: MME=microcystic macular edema; ON=optic neuritis; mRNFL=macular retinal nerve fiber layer; GCIPL =ganglion cell and inner plexiform layer;
INL = inner nuclear layer; SD = standard deviation; GEE =generalized estimation equation.
doi:10.1371/journal.pone.0071145.t004
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based on same mechanisms as in MS and related inflammatory
diseases or are rather merely similar symptoms with different
etiologies. However, histopathological data on reduced neuronal
cell counts in the INL in MS [29] and our findings of INL
thickening in ON eyes strongly suggest that INL changes
contribute significantly to retinal pathology in optic neuritis-
associated diseases. Furthermore, INL changes were recently
demonstrated in a rodent model of MS in the form of microcystic
disruption or repair-associated loosening of the INL layer, which
Figure 3. Sample quantification of SLO MME area. A) Quantification of the MME-affected area of a sample eye in a SLO image with ImageJ. B)
The microcysts in OCT B-scans of the same sample eye mapped onto the SLO image. The yellow lines correspond to the spread of the macular edema
in the two example B-scans at the bottom.
doi:10.1371/journal.pone.0071145.g003
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supports the hypothesis of increased INL thickness in relation to
optic nerve inflammation [49].
We could identify MME with high sensitivity and specificity
using SLO images, a technique previously reported as promising
in a case report [33]. In a blinded analysis, every MME detected
on a B-scan had a clearly visible equivalent on the corresponding
SLO image. Based on these findings, SLO image analysis may be
superior to the more time-consuming inspection of a high number
of B-scans for MME detection in daily routine. The fact that more
eyes were classified as MME-affected in the blinded SLO analysis
than in B-scan detection could be explained by the dynamics of
microcystic changes, which might be different from the alterations
found on OCT B-scans. Ultimately, with no gold standard means
of confirmation (i.e. by histology), our study cannot determine
whether the additional positive SLO scans were false positives or
the corresponding OCT B-scans were false negatives.
The size of MME, as quantified by SLO images analysis, was
inversely correlated with the length of time between prior ON and
OCT examination: the shorter the interval between the clinical
event of ON and OCT scan, the larger the MME-affected surface
in the SLO image. Secondly, eyes with low visual acuity showed
larger textural changes in SLO images than eyes with high visual
acuity in patients with MME. Finally, MME-affected eyes showed
significantly stronger RNFL thinning and poorer visual acuity than
MME-unaffected eyes with a history of ON. These findings
support the hypothesis that MME is a result of severe optic neuritis
events and may contribute to a poor visual outcome following
optic neuritis. However, given the cross-sectional design of our
study and the in some cases long intervals between previous
clinical ON, as documented or reported by patients, and MME
diagnosis, these results should be interpreted with caution.
Temporal dynamics of MME subsequent to ON will have to be
addressed in longitudinal studies with frequent OCT scans
following the clinical event.
Some important caveats deserve mention. Like the work by
Gelfand et al. and Saidha et al., our study was a retrospective
analysis, including assessment of previous ON events without the
benefit of first-hand observation. While carries a theoretical risk of
misclassification the high accordance of our findings with those in
previous MME studies suggests methodological bias in our study is
probably limited. Moreover, we examined a rather small cohort of
CRION and NMOSD patients, which produced a very high rate
of MME in these entities (56% and 15%, respectively) compared
to MME prevalence in MS. The small number of these patients in
our study reflect the relatively low prevalence of these diseases
[34,50], but cohort size should be increased in further studies.
Although the prevalence of MME varied between the three
conditions, group comparisons should be interpreted with caution
due to the relatively low sample size in the NMOSD and CRION
groups and the overall low frequency of MME. Moreover, we
cannot exclude the possibility that some of the CRION cases may
evolve into an MS or NMOSD diagnosis with a longer duration of
observation. Furthermore, the quantification of MME-affected
areas in SLO images includes a potential grader bias. Further
verification is required to establish the MME-affected area in SLO
images as an accepted marker for the degree of retinal damage
caused by MME.
In summary, we show that INL thickening and MME occur in
various neuro-inflammatory disorders and are strongly linked to
ON events and decreased visual acuity. We also provide data that
identification and quantification of MME using SLO images
generated by the OCT device is easier than using the established
technique of B-scans, and may lend itself to clinical application in
the future. In the final instance, the causative role of ON for MME
and the dynamics of INL thickening and MME formation can
only be elucidated in a longitudinal study on patients with acute
optic neuritis.
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